Loading...
Market
How many patients will be prescribed Lecanemab in the UK by December 31, 2025?
2
Resolution / Starting Odds
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,000 to 30,000 • 25%
More than 30,000 • 25%
Reports from the National Health Service (NHS) or major healthcare providers
Story
Alzheimer's Wonder Drug Lecanemab, Biggest Breakthrough in Decades, Set for UK Approval
Aug 21, 2024, 11:46 PM
The Alzheimer's wonder drug Lecanemab is set to receive approval for use in Britain, marking a significant advancement in the treatment of the disease. This drug is the first to demonstrate the ability to slow down the progression of Alzheimer's, offering new hope to patients and healthcare providers. The approval is expected to allow Lecanemab to be prescribed privately, with potential for future availability through the National Health Service (NHS). The Medicines and Healthcare products Regulatory Agency (MHRA) is anticipated to make a favorable decision soon. While not a cure, Lecanemab represents a crucial step forward in Alzheimer's treatment, highlighting the need for increased investment in dementia services and early diagnosis. Described as the biggest breakthrough in decades, this development underscores the importance of continued research and support for Alzheimer's patients.
View original story
Similar markets
Less than 500 • 25%
500 to 1000 • 25%
1001 to 2000 • 25%
More than 2000 • 25%
Less than £1000 • 25%
£1000 to £2000 • 25%
£2001 to £3000 • 25%
More than £3000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 100 • 25%
100 to 500 • 25%
500 to 1000 • 25%
More than 1000 • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
